What are the major opportunities in the Lung Cancer Drugs market? What are the strategies for the Lung Cancer Drugs market?

For detailed insights on the major opportunities and strategies in the Lung Cancer Drugs market, Read More

How does the Lung Cancer Drugs market relate to the overall economy and other similar markets?

For detailed insights on Lung Cancer Drugs's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Lung Cancer Drugs market growth? SWOT analysis of the Lung Cancer Drugs market.

For detailed insights on the key dynamics influencing the Lung Cancer Drugs market growth and SWOT analysis of the Lung Cancer Drugs industry, Read More

Lung Cancer Drugs Market Global Report 2026 Market Report Infographic Image

Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Lung Cancer Drugs Market Report 2026

Name: Lung Cancer Drugs Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs ), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By End User (Hospitals, Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Lung Cancer Drugs Market Overview

• Lung Cancer Drugs market size has reached to $52.98 billion in 2025

• Expected to grow to $88.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%

• Growth Driver: Rising Prevalence Of Lung Cancer Driving Market Growth Due To Increased Need For Cost-Efficient And Advanced Therapeutic Options

• Market Trend: Embedding First-Line Chemotherapy-Free Targeted Therapies For EGFR-Mutated Advanced Lung Cancer

• North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Lung Cancer Drugs Market?

Lung cancer drugs refer to anti-angiogenic drugs that are used to treat lung cancer. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The main types of diseases in lung cancer drugs are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a type of lung cancer that grows quickly in the lungs' tissues. Small cell lung cancer has often expanded (metastasized) outside of the lungs by the time a person receives a diagnosis. This malignancy is also more likely to recur after therapy than other types of lung cancer. The different types of drugs include Gemzar, paraplatin, Taxotere, navelbine, avastin, Tarceva, Iressa, and others and are used in various sectors such as hospitals, clinics, and others.

Lung Cancer Drugs Market Global Report 2026 Market Report bar graph

What Is The Lung Cancer Drugs Market Size and Share 2026?

The lung cancer drugs market size has grown strongly in recent years. It will grow from $52.98 billion in 2025 to $58.23 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to high smoking prevalence, rising lung cancer incidence, widespread chemotherapy adoption, expansion of oncology hospitals, increased availability of generic cancer drugs.

What Is The Lung Cancer Drugs Market Growth Forecast?

The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $88.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growth in targeted and immunotherapy drugs, increasing lung cancer screening rates, rising healthcare expenditure in oncology, aging population, expansion of combination therapy approvals. Major trends in the forecast period include rising adoption of targeted lung cancer therapies, increased use of combination drug regimens, growing focus on early-stage lung cancer treatment, expansion of personalized treatment protocols, increasing hospital-based administration of oncology drugs.

Book your 30 minutes free consultation with our research experts

Global Lung Cancer Drugs Market Segmentation

1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)

3) By End User: Hospitals, Clinics, Other End-Users

What Is The Driver Of The Lung Cancer Drugs Market?

The rising prevalence rate of lung cancer is expected to drive the growth of the lung cancer drugs market going forward. Lung cancer is a life-threatening malignancy that requires timely and effective treatment, including chemotherapy, targeted therapies, immunotherapies, and combination regimens to improve survival outcomes. The rise in cases of lung cancer is primarily due to environmental pollution and exposure to carcinogens, alongside genetic predisposition, which collectively contribute to lung cell mutations even in non-smokers. The growing prevalence of lung cancer supports the lung cancer drugs by boosting demand for more effective treatment solutions capable of improving life expectancy, reducing tumor progression, and enhancing quality of life for patients. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 deaths from lung cancer (67,160 in men and 59,910 in women) were estimated in 2023. Therefore, the rising prevalence rate of lung cancer is driving the growth of the lung cancer drugs industry.

Key Players In The Global Lung Cancer Drugs Market

Major companies operating in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC

Global Lung Cancer Drugs Market Trends and Insights

Major companies operating in the lung cancer drugs market are focusing on product innovation and formulation such as chemotherapy-free combination therapies targeting EGFR mutations, to enhance treatment efficacy, reduce systemic toxicity, and improve quality of life for patients with advanced non-small cell lung cancer (NSCLC). These therapies enable precision oncology approaches, offering targeted inhibition of specific molecular pathways driving tumor growth. For instance, in August 2024, Johnson & Johnson, a US-based pharmaceutical company, received U.S. FDA approval for Rybrevant plus Lazcluze as a first-line, chemotherapy-free treatment for patients with EGFR-mutated advanced NSCLC. The combination therapy is designed to provide dual inhibition of EGFR and MET pathways, offering enhanced anti-tumor activity while minimizing exposure to traditional chemotherapy side effects. This approval reflects a growing trend in the lung cancer market toward personalized, targeted treatment regimens that improve outcomes and patient experience by reducing reliance on conventional chemotherapy.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Lung Cancer Drugs Market?

In January 2024, Bristol-Myers Squibb, a US-based biopharmaceutical company, acquired Mirati Therapeutics, for approximately $4.8 billion. Through this acquisition, Bristol-Myers Squibb aims to enhance its lung cancer drug portfolio by integrating Mirati’s targeted therapies, including KRAS G12C inhibitors, to provide innovative treatment options for patients with advanced and metastatic lung cancer. Mirati Therapeutics is a US-based biotechnology company, specializes in the development of precision oncology therapies with a strong track record in lung cancer drug development.

Regional Insights

North America was the largest region in the lung cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lung Cancer Drugs Market?

The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lung Cancer Drugs Market Report 2026?

The lung cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Lung Cancer Drugs Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$58.23 billion
Revenue Forecast In 2035	$88.06 billion
Growth Rate	CAGR of 9.9% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drugs, Disease Type, End User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical I
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Lung Cancer Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Lung Cancer Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Lung Cancer Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Lung Cancer Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Rising Adoption Of Targeted Lung Cancer Therapies

4.2.2 Increased Use Of Combination Drug Regimens

4.2.3 Growing Focus On Early-Stage Lung Cancer Treatment

4.2.4 Expansion Of Personalized Treatment Protocols

4.2.5 Increasing Hospital-Based Administration Of Oncology Drugs

5. Lung Cancer Drugs Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Oncology Clinics

5.3 Cancer Treatment Centers

5.4 Specialty Hospitals

5.5 Ambulatory Oncology Units

6. Lung Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Lung Cancer Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Lung Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Lung Cancer Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Lung Cancer Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Lung Cancer Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Lung Cancer Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Lung Cancer Drugs Market Segmentation

9.1. Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

9.2. Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)

9.3. Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Clinics, Other End-Users

10. Lung Cancer Drugs Market Regional And Country Analysis

10.1. Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Lung Cancer Drugs Market

11.1. Asia-Pacific Lung Cancer Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Lung Cancer Drugs Market

12.1. China Lung Cancer Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Lung Cancer Drugs Market

13.1. India Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Lung Cancer Drugs Market

14.1. Japan Lung Cancer Drugs Market Overview

14.2. Japan Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Lung Cancer Drugs Market

15.1. Australia Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Lung Cancer Drugs Market

16.1. Indonesia Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Lung Cancer Drugs Market

17.1. South Korea Lung Cancer Drugs Market Overview

17.2. South Korea Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Lung Cancer Drugs Market

18.1. Taiwan Lung Cancer Drugs Market Overview

18.2. Taiwan Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Lung Cancer Drugs Market

19.1. South East Asia Lung Cancer Drugs Market Overview

19.2. South East Asia Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Lung Cancer Drugs Market

20.1. Western Europe Lung Cancer Drugs Market Overview

20.2. Western Europe Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Lung Cancer Drugs Market

21.1. UK Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Lung Cancer Drugs Market

22.1. Germany Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Lung Cancer Drugs Market

23.1. France Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Lung Cancer Drugs Market

24.1. Italy Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Lung Cancer Drugs Market

25.1. Spain Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Lung Cancer Drugs Market

26.1. Eastern Europe Lung Cancer Drugs Market Overview

26.2. Eastern Europe Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Lung Cancer Drugs Market

27.1. Russia Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Lung Cancer Drugs Market

28.1. North America Lung Cancer Drugs Market Overview

28.2. North America Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Lung Cancer Drugs Market

29.1. USA Lung Cancer Drugs Market Overview

29.2. USA Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Lung Cancer Drugs Market

30.1. Canada Lung Cancer Drugs Market Overview

30.2. Canada Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Lung Cancer Drugs Market

31.1. South America Lung Cancer Drugs Market Overview

31.2. South America Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Lung Cancer Drugs Market

32.1. Brazil Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Lung Cancer Drugs Market

33.1. Middle East Lung Cancer Drugs Market Overview

33.2. Middle East Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Lung Cancer Drugs Market

34.1. Africa Lung Cancer Drugs Market Overview

34.2. Africa Lung Cancer Drugs Market, Segmentation By Drugs, Segmentation By Disease Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Lung Cancer Drugs Market Regulatory and Investment Landscape

36. Lung Cancer Drugs Market Competitive Landscape And Company Profiles

36.1. Lung Cancer Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Lung Cancer Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Lung Cancer Drugs Market Company Profiles

36.3.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Lung Cancer Drugs Market Other Major And Innovative Companies

GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited

38. Global Lung Cancer Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Lung Cancer Drugs Market

40. Lung Cancer Drugs Market High Potential Countries, Segments and Strategies

40.1 Lung Cancer Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Lung Cancer Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Lung Cancer Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Lung Cancer Drugs Market, Overview Of Key Products - Product Examples

Table 2: Global Lung Cancer Drugs Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Lung Cancer Drugs Market, Supply Chain Analysis

Table 4: Global Lung Cancer Drugs Market, Major Raw Material Providers

Table 5: Global Lung Cancer Drugs Market, Major Resource Providers

Table 6: Global Lung Cancer Drugs Market, Major Manufacturers (Suppliers)

Table 7: Global Lung Cancer Drugs Market, Major Distributors And Channel Partners

Table 8: Global Lung Cancer Drugs Market, Key Technologies & Future Trends

Table 9: Global Lung Cancer Drugs Market, Major Trends

Table 10: Global Lung Cancer Drugs Market, Major End Users

Table 11: Global Lung Cancer Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Lung Cancer Drugs Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Lung Cancer Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Lung Cancer Drugs Market - TAM, US$ Billion, 2025

Table 15: Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: China, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: China, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: China, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: India, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: India, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: India, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: Japan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: Japan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: Japan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: Australia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Australia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Australia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Indonesia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Indonesia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Indonesia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: South Korea, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: South Korea, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: South Korea, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Taiwan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Taiwan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Taiwan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South East Asia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South East Asia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South East Asia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Western Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Western Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Western Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: UK, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: UK, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: UK, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Germany, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Germany, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Germany, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: France, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: France, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: France, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Italy, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Italy, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Italy, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Spain, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Spain, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Spain, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Eastern Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Russia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Russia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Russia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: North America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: North America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: North America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: USA, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: USA, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: USA, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: Canada, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: Canada, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: Canada, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: South America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: South America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: South America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Brazil, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Brazil, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Brazil, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Middle East, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Middle East, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Middle East, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Africa, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Africa, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Africa, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Global Lung Cancer Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 93: Global Lung Cancer Drugs Market - Company Scoring Matrix

Table 94: Bristol-Myers Squibb Company Financial Performance

Table 95: Merck & Co. Inc. Financial Performance

Table 96: F. Hoffmann-La Roche Ltd. Financial Performance

Table 97: Novartis AG Financial Performance

Table 98: Pfizer Inc. Financial Performance

Table 99: Global Lung Cancer Drugs Market, Competitive Benchmarking (In USD Billions)

Table 100: Global Lung Cancer Drugs Market, Competitive Dashboard

Table 101: Global Lung Cancer Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 102: Global, Lung Cancer Drugs Market Size Gain ($ Billion), Segmentation By Drugs, 2025 – 2030

Table 103: Global, Lung Cancer Drugs Market Size Gain ($ Billion), Segmentation By Disease Type, 2025 – 2030

Table 104: Global, Lung Cancer Drugs Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

List Of Figures

Figure 1: Global Lung Cancer Drugs Market, Overview Of Key Products - Product Examples

Figure 2: Global Lung Cancer Drugs Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Lung Cancer Drugs Market, Supply Chain Analysis

Figure 4: Global Lung Cancer Drugs Market, Major Raw Material Providers

Figure 5: Global Lung Cancer Drugs Market, Major Resource Providers

Figure 6: Global Lung Cancer Drugs Market, Major Manufacturers (Suppliers)

Figure 7: Global Lung Cancer Drugs Market, Major Distributors And Channel Partners

Figure 8: Global Lung Cancer Drugs Market, Key Technologies & Future Trends

Figure 9: Global Lung Cancer Drugs Market, Major Trends

Figure 10: Global Lung Cancer Drugs Market, Major End Users

Figure 11: Global Lung Cancer Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Lung Cancer Drugs Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Lung Cancer Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Lung Cancer Drugs Market - TAM, US$ Billion, 2025

Figure 15: Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: China, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: China, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: China, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: India, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: India, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: India, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: Japan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: Japan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: Japan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: Australia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Australia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Australia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Indonesia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Indonesia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Indonesia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: South Korea, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: South Korea, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: South Korea, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Taiwan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Taiwan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Taiwan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South East Asia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South East Asia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South East Asia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Western Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Western Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Western Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: UK, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: UK, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: UK, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Germany, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Germany, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Germany, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: France, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: France, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: France, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Italy, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Italy, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Italy, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Spain, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Spain, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Spain, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Eastern Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Russia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Russia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Russia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: North America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: North America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: North America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: USA, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: USA, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: USA, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: Canada, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: Canada, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: Canada, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: South America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: South America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: South America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Brazil, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Brazil, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Brazil, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Middle East, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Middle East, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Middle East, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Africa, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Africa, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Africa, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Global Lung Cancer Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 93: Global Lung Cancer Drugs Market - Company Scoring Matrix

Figure 94: Bristol-Myers Squibb Company Financial Performance

Figure 95: Merck & Co. Inc. Financial Performance

Figure 96: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 97: Novartis AG Financial Performance

Figure 98: Pfizer Inc. Financial Performance

Figure 99: Global Lung Cancer Drugs Market, Competitive Benchmarking (In USD Billions)

Figure 100: Global Lung Cancer Drugs Market, Competitive Dashboard

Figure 101: Global Lung Cancer Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 102: Global, Lung Cancer Drugs Market Size Gain ($ Billion), Segmentation By Drugs, 2025 – 2030

Figure 103: Global, Lung Cancer Drugs Market Size Gain ($ Billion), Segmentation By Disease Type, 2025 – 2030

Figure 104: Global, Lung Cancer Drugs Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

Industry Forecast: Plasma Fractionation Market to Generate $50.54 Billion Revenue by 2029

CAGR of 11.4% Projected for Protein Purification and Isolation Market From 2025 to 2029

Emerging Trends and Growth Drivers in the Pulmonary Arterial Hypertension Market Through 2029

Latest Market Developments in Specialty Generics Industry: Forecast 2025–2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

Metastatic Cancer Drugs Market Report 2026 - Global Outlook – By Drug Class (HER2 Inhibitors, Immune Checkpoints Inhibitors, PARP Inhibitors, Kinase Inhibitors, Other Drug Class), By Cancer (Breast Cancer, Lung Cancer, L...

Lung Cancer Drugs Market Report 2026 - Global Outlook – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs ), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung canc...

Respiratory Diseases Drugs Global Market Report 2022 – By Type (Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Adm...

Non-Small Cell Lung Cancer (NSCLC) Market Report 2026 - Global Outlook – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laser Therapy, Photodynamic Therapy...

Small Cell Lung Cancer Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Atezolizumab, Topotecan, Lurbinectedin, Durvalumab, Methotrexate, Pembrolizumab), By Treatment Type (Chemotherapy, Targeted Therapy,...

Frequently Asked Questions

What is the projected market size of the Lung Cancer Drugs Market Report 2026 market by 2030?

The Lung Cancer Drugs Market Report 2026 market was valued at $52.98 billion in 2025, increased to $58.23 billion in 2026, and is projected to reach $88.06 billion by 2030. request a sample here

What is the expected CAGR for the Lung Cancer Drugs Market Report 2026 market during the forecast period 2025 - 2030?

The expected CAGR for the Lung Cancer Drugs Market Report 2026 market during the forecast period 2025–2030 is 10.9%. request a sample here

What are the key factors driving the Lung Cancer Drugs Market Report 2026 market?

Major growth driver of the market includes: Rising Prevalence Of Lung Cancer Driving Market Growth Due To Increased Need For Cost-Efficient And Advanced Therapeutic Options in the Lung Cancer Drugs Market Report 2026 market. For further insights on this market, request a sample here

Which end-use segment are covered in the Lung Cancer Drugs Market Report 2026 market report?

The lung cancer drugs market covered in this report is segmented –
1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs
2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)
3) By End User: Hospitals, Clinics, Other End-Users request a sample here

What is the anticipated growth trend for the Lung Cancer Drugs Market Report 2026 market?

Major trend in this market includes: Embedding First-Line Chemotherapy-Free Targeted Therapies For EGFR-Mutated Advanced Lung Cancer For further insights on this market, request a sample here.

Who are the key players in the Lung Cancer Drugs Market Report 2026 market?

Major companies operating in the Lung Cancer Drugs Market Report 2026 market are Major companies operating in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmi request a sample here.

North America was the largest region in the lung cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. request a sample here.

Book your 30 minutes free consultation with our research experts

Contact Us